In patients with heart failure and reduced left ventricular ejection fraction (LVEF< 35%), there
is an increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias (VA), with …

Abstract Background Implantable cardioverter defibrillators (ICDs) reduce all‐cause
mortality among cardiomyopathy patients. Whether or not antitachycardia pacing (ATP) is …

Abstract Purpose of Review Implantable cardioverter-defibrillator (ICD) shocks, whether
appropriate or inappropriate, are associated with significant morbidity and mortality. Anti …

Antitachycardia pacing (ATP) strategies represent safe, effective, and painless therapy for
ventricular tachyarrhythmias, with a large body of clinical evidence supporting their routine …

Programming ATP for ICD Patients. Objectives: The PROVE trial was designed to determine
if antitachycardia pacing (ATP) is clinically beneficial for primary prevention in patients who …

The first implantable cardioverter-defibrillator (ICD) device was developed by Drs Michel
Mirowski and Morty Mower, and successfully implanted in a human being at John Hopkins …

The role of the implantable cardioverter-defibrillator (ICD) is well established as a lifesaving
intervention in patients with both severe ischemic (ICM) and non-ischemic (NICM) …

ATP and Mortality in 69,000 ICD Patients Aims Antitachycardia pacing (ATP) is an effective
treatment for ventricular tachycardia (VT) and can reduce the frequency of shocks in patients …

Background Antitachycardia pacing (ATP) is an established implantable cardioverter-
defibrillator (ICD) therapy that terminates ventricular tachycardias (VTs) without painful ICD …

In clinical practice, most implantable-cardioverter defibrillators (ICDs) are implanted for
primary prevention of sudden death, and the most common therapy ICDs deliver is …